Immuneering announces the publication of “Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse” in PLoS ONE

April 3, 2013. Cambridge, MA.  Immuneering Corporation is pleased to announce the publication of “Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse” in PLoS ONE, with co-authors including Immuneering’s VP of Biocomputing Dr. Fadi Towfic and the co-chair of Immuneering’s scientific advisory board, Dr. Max Artyomov.   The study was led by a distinguished team of investigators at Washington University in St. Louis, and provides new insight into the development of type 1 diabetes.  An Immuneering-developed proprietary algorithm helped to identify changes in the types of immune cells present as diabetes develops, based on gene expression (microarray) data.   The cell-type enrichment algorithm used in this study is one example of the broad range of cutting edge proprietary computational methods that Immuneering develops and uses to extract biological insights from molecular-level data, provide insight into disease biology, and facilitate the development of new medicines.  Co-author Dr. Fadi Towfic summed up the results, saying “It is quite exciting to be part of this unique endeavor to examine autoimmune disease through the lens of the contributing immune cell types. The results will help in understanding the complex dynamics of autoimmunity and developing more targeted medicines.”  Co-Author Dr. Max Artyomov agreed, saying “The data and analysis in this work will provide a long-standing basis for pre-clinical diabetes staging based on the characterization of islet infiltrating cells and their transcriptomes. It is very exciting to be a part of the team working on this topic.”